News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups
Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups
Hosted by Robert Michel
Sign In

Illumina Is Using Acquisitions to Challenge Roche in Fast-growing Market for Gene-based Clinical Pathology Laboratory Testing

Nov 23, 2012 | Laboratory Hiring & Human Resources, Laboratory News, Laboratory Pathology

Hot competition for genetic testing market share is a signal to medical laboratories to ramp up their molecular and genetic testing capabilities

Financial analysts see something of an “old west” style shootout on the horizon for genetic testing in the clinical laboratory testing market. Market leaders in next-generation gene sequencing are prepared to use acquisitions to build dominant shares in a gene testing market that experts say could hit $25 billion by 2022.

Reporters at Bloomberg Businessweek believe that San Diego-based Illumina, Inc. (NASDAQ: ILMN) is girding up to take on industry giant Roche Holding AG (ROG.VX). Both Illumina and Life Technologies Corp. (NASDAQ:LIFE) are buying up smaller players in the gene testing market.

These two market leaders in DNA sequencing equipment have played important roles in revolutionizing genetic testing. Now, they intend to stake out a share of the fast-growing genetic diagnostics market themselves, a recent Businessweek story reported. (more…)

Roche Diagnostics to Invest a Whopping $300 Million in Indianapolis to Support Expansion of its Clinical Lab Testing Business

Aug 20, 2012 | Laboratory Hiring & Human Resources, Laboratory News, Laboratory Pathology

Roche is refocusing its resources as it works to rebalance its businesses in pharmaceuticals and clinical laboratory testing

Roche Diagnostics is pumping $300 million into its North American headquarters in Indianapolis. At the same time, the Roche research and development campus in Nutley, New Jersey will be closed. Collectively both actions are a sign of the company’s confidence in the growth prospects for clinical laboratory testing, molecular diagnostics, and genetic testing.

Many pathologists are aware that Roche Diagnostics has experienced rapid year-over-year growth in its molecular diagnostics business. The company wants to expand its facilities to support further growth in this sector. (more…)

;